EU needs to modify existing guidance for nanotech risk assessment
This article was originally published in Clinica
Modifications to the existing EU technical guidance for the risk assessment of chemicals will be necessary for nanomaterials, including those used in medical technology. That is the view of the EU's Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR), which has just published a scientific opinion on the appropriateness of the EU Technical Guidance Documents for chemicals in regard to nanomaterials.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.